Celltrion Inc.
Scope
Date
~
-
Shareholder value
Korea Inc. ups dividend payouts despite falling net income
South Korean companies listed on the main bourse Kospi raised their dividend payouts between 2021 and 2023 despite falling net income in the same pe...
May 10, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
May 02, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion releases Remsima SC in Denmark
South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...
Apr 19, 2024 (Gmt+09:00)
-
Bio & Pharma
Korea’s Celltrion, SK Biopharmaceuticals benefit from direct US sales
Celltrion Inc. and SK Biopharmaceuticals Co. are witnessing improving sales revenue and profitability by selling their products through their own ma...
Apr 16, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion'a autoimmune disease drug Zymfentra makes US debut
South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...
Mar 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion ships initial supply of Zymfentra to US
South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...
Feb 29, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to deliver three treatments to Peru
South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...
Feb 15, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima SC, Yuflyma to Norway
South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...
Feb 07, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion, WuXi XDC to develop new antibody-drug conjugates
South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...
Jan 24, 2024 (Gmt+09:00)
-
Banking & Finance
Korean banks flock to Poland, Korean Inc.’s new manufacturing hub
South Korean banks are in a race to advance into Poland to support Korean companies rushing to build factories in the new offshore manufacturing hub...
Jan 22, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to export three anticancer drugs to Europe
South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...
Jan 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman
South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the...
Jan 16, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand Yuflyma supply network in Europe
South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...
Jan 12, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion revises up earnings goals to overtake Amgen
Celltrion Inc., South Korea's leading biosimilar maker, on Wednesday expressed its ambition to join the global top 10 biotech and pharmaceutical com...
Jan 11, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for interchangeability of Yuflyma in US
South Korea's Celltrion Inc. announced on Wednesday that it has applied to the US Food and Drug Administration (FDA) for a modified approval to repl...
Jan 10, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion to sell portfolio of Takeda drugs to CBC Group
South Korea’s Celltrion Inc. will divest of a portfolio of Takeda Pharmaceutical's prescription medicines sold in Asia to CBC Group, a Singapo...
Jan 01, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval of Xolair biosimilar in Canada
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...
Dec 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Vegzelma listed on US PBM preferred drug list
South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as ...
Dec 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare's Herzuma selected as funded brand in NZ
Celltrion Healthcare Co. announced on Thursday that its biosimilar anticancer drug Herzuma (active ingredient trastuzumab) for breast and gastr...
Dec 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Cyron to develop multi-specific antibody new drug
South Korea’s biopharmaceutical company Celltrion Inc. announced on Wednesday that it signed a joint research agreement with domestic startup ...
Dec 06, 2023 (Gmt+09:00)
-
Executive reshuffles
SK Chair Chey calls on cousin for help in group management
SK Group Chairman Chey Tae-won has called on his cousin to help in the management of South Korea’s No. 2 conglomerate as it faces the challeng...
Dec 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare's Remsima SC to be launched in US in 2024
Celltrion Healthcare Co. announced on Thursday that its autoimmune disease treatment Zymfentra (the US product name for Remsima SC) is set to be lau...
Nov 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in Europe for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...
Nov 24, 2023 (Gmt+09:00)
-
Business & Politics
Korea Inc.’s dividend repatriation soars on new tax breaks
Major companies in South Korea, such as affiliates of Samsung, LG and Hyundai Motor Group, are bringing larger amounts of capital back back home fro...
Nov 19, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima to Brazil gov’t in three-year row
South Korea's Celltrion Healthcare Co. announced on Friday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for the B...
Nov 10, 2023 (Gmt+09:00)
-
Earnings
Celltrion enjoys record earnings on healthy biosimilar biz
South Korean pharmaceutical giant Celltrion Inc. logged record quarterly earnings on the strong performance of its key biosimilar products while exp...
Nov 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s approved merger removes hurdle to three-way combination
South Korea’s biosimilar drugmaker Celltrion group on Monday moved one step closer to the planned combination of its three major affiliates wi...
Oct 23, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets FDA approval for Remsima SC
South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient i...
Oct 23, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare wins Remsima order in France, Italy
South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for ho...
Oct 18, 2023 (Gmt+09:00)
-
Economy
Korea Inc.’s record short-term borrowing raises specter of debt overhang
South Korea’s short-term corporate loan growth is picking up at a fast pace, stirring concern among some analysts who see parallels to the 200...
Oct 18, 2023 (Gmt+09:00)